21-hydroxylase deficiency risk factors: Difference between revisions
No edit summary |
Aditya Ganti (talk | contribs) |
||
| Line 22: | Line 22: | ||
[[Category:Intersexuality]] | [[Category:Intersexuality]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Up-To-Date]] | [[Category: Up-To-Date]] | ||
Latest revision as of 15:37, 24 July 2020
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency risk factors On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency risk factors |
|
Risk calculators and risk factors for 21-hydroxylase deficiency risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
The most potent risk factor in the development of 21-hydroxylase deficiency is presence of family history of 21-hydroxylase deficiency, and belonging to certain ethnic groups, particularly Ashkenazi Jews, Yugoslavians and Yupik Inuits.
Risk Factors
The most potent risk factors in the development of 21-hydroxylase deficiency are:
- Presence of family history of 21-hydroxylase deficiency.
- Belonging to certain ethnic groups, particularly Ashkenazi Jews, Yugoslavians and Yupik Inuits.[1][2]
References
- ↑ Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.